Dr. Rūta Gancevičienė
Conference President EHSF 2025
President of the Lithuanian Association of Dermatovenerology

Sponsors

Platinum
Abbvie
Novartis
UCB

Silver
Incyte
Moonlake Immunnotherapeutics

Dear colleagues,

Welcome to the 13th edition of the European Hidradenitis Suppurativa Foundation Conference in Lyon!​

With the emergence of innovative biologics, combined with surgical strategies, the HS community is undergoing a remarkable revolution. The EHSF is the congress to discuss cutting edge data and emergent therapeutic strategies in HS; with the latest revelations in clinical and fundamental research, or the most ardent debates on diagnostic and treatments.​

There is indeed still so much to be done to improve the care of HS patients! This meeting will be a wonderful opportunity for scientists, caregivers and patients to connect in a multidisciplinary hub. ​

With Lyon hosting the EHSF, attendees will enjoy exciting social programs, the warmest hospitality, and the most exquisite traditional French cuisine. ​

We are delighted and honored to host the 13th EHSF in Lyon, eagerly anticipating your passionate response to these fundamental issues.

Philippe GUILLEM, MD, PhD
Congress President
Dept of Surgery,
Clinique du Val d’Ouest,
Ecully

Axel VILLANI, MD, PhD
Congress President
Dept of Dermatology,
Hôpital Edouard Herriot,
Hospices Civils de Lyon

Sponsors

Platinum
Abbvie
Novartis
UCB

Silver
BOEHRINGER INGELHEIM
Incyte

Dear colleagues,

We are very proud to welcome you in Florence for the 12th Conference of the European
Hidradenitis Suppurativa Foundation. The Conference will be held in a hybrid mode from 8th
to 10th February 2023.

In recent years, there has been growing interest within scientific community about
hidradenitis suppurativa (HS), as demonstrated by the outstanding attendance at this
event. After years of remote events, EHSF 2023 will be an excellent opportunity to meet
again in person around the most exciting scientific works and meet and discuss with experts
on specific topics.

In this Conference, we have tried to involve as many representatives of
different disciplines as possible, in an attempt to make multidisciplinary teamwork the norm
rather than the exception. Our target for this Conference is to re-consider the HS patient
as part of a human-centered medicine according to the Renaissance style and no city like
Florence could have been more suitable for this ambitious purpose.

Francesca Prignano, MD, PhD
Associate Professor
Dept. Health Sciences,
Div. Dermatology – University of Florence Medical School,
Firenze, Italy

Sponsors

Platinum
Abbvie

Gold
Novartis
UCB

Silver
BOEHRINGER INGELHEIM
Incyte

Other
Almirall
Amgen
Eli Lilly Italy
Janssen Italy
Molteni Therapeutics
Sanofi
Unifarco
Abiogen
Biodue
Biogen Italia
Bionike
Difa Cooper – Cantabria Labs
Leo Pharma Italy
Novartis Italy

Dear colleagues,

The EHSF e.V. celebrates 15 years of fascinating work mirrored in a current publication of 43
coauthors (Exp Dermatol 2020;29:1154–70), which summarized ongoing hidradenitis suppurativa
(HS) research and clinical activities around the globe.
After the international thematic conferences in Dessau (2006), San Francisco (2009),
Brussels (2014 and 2015), Berlin (2016), Copenhagen (2017), Rotterdam (2018), Wroclaw (2019)
and Athens (2020) we had planed to organize the 10th International EHSF Conference as a
worldwide face-to-face event. The pandemic has obliged us, however, to offer a virtual event,
which is a new experience for us and, despite of that, is going to fulfill our target to provide a
high level scientific event on the ongoing and future research development and innovations on
HS. Moreover, we want to achieve our initial purpose to encourage international cooperation in
the field.

Since the legendary, pioneer days many things have changed to the better. The interest to the
disease and the scientific work performed by increasing numbers of clinician and scientists
have grown exponentially. HS has found its home in dermatology. Patients have been
organized in several national self-aid groups. A first compound for medical treatment has
been registered with many more currently being into clinical studies. At last, the EHSF e.V. has
grown up, providing significant contributions in the field through valuable cooperative works
of its members in discovering the molecular etmiology, comorbid factors and biomarkers, and
establishing diagnostic and classification criteria, outcome measure instruments and guidelines
for the treatment of the disease.

These huge developments, which supported a better understanding of HS and the needs of
medical and psychological care of HS patients but also the targets for the years to come will
be the central subjects of this scientific event. Parallelly, EHSF e.V. opens its doors to invite all
caring physicians and scientists, independently of their specialization, to participate, since the
emerging comorbidity of HS requires an interdisciplinary approach. Our purpose is to construct
a scientific programme of high impact providing current information on research and clinical
relevance on HS. The invited speakers and those chosen among you, who will submit abstracts,
include both experts in the field, who are motivators for young upcoming specialists, but also
young scientists and students working or wishing to work in this fascinating field in the future
as well as the partners of the pharmaceutical industry, who are active in the field.

Participants will have the opportunity to share their knowledge and perspectives and to gain a
better insight in HS. We have no doubt that your virtual journey to Europe will be an interesting
experience and we will make our best efforts that your scientific expectations and networking
wishes will be fulfilled.

On behalf of the EHSF e.V

Prof. Dr. med. Prof. honoraire Dr. h.c. Christos C. Zouboulis
Dessau

Sponsors

Platinum
Abbvie

Silver
Incyte
Novartis
UCB